Endoplasmic reticulum (ER), Golgi apparatus (GA), and lysosomes are the endomembrane system of cells. These structures exchange membrane material via a special type of transport. Earlier studies have shown that ER-GA network may be a target for anti-cancer therapy. A new study reported in the Journal of Clinical Investigation finds that GA is involved in the metastasis of lung cancer, and certain proteins including PAQR11 in it actually drive cancer metastasis. The study was carried out by Prof. Jonathan Kurie and colleagues from the University of Texas MD Anderson Cancer Center, in collaboration with researchers from Ewha Womans University School of Medicine, University of Michigan, University of York, and other institutes. Their findings support that the Golgi may provide an approach for halting cancer metastasis. GA, also called Golgi body or Golgi complex, is found universally in eukaryotic cells and was identified by an Italian biologist Camillo Golgi in 1897. It can collect, modify, package, and distribute proteins and lipids. For this reason, it's also called the shipping and receiving department of the cell. In fact, GA packages proteins and lipids into small membrane vesicles, which often migrate to and merge with the plasma membrane. Kurie's team found that a transcription factor bubbled Zeb1 can send a signal to the Golgi scaffolding protein PAQR11. This communication promotes membrane vesicle transport in GA, which in turn alters the perimeter of the cancer cell and allows it to move to other parts of the body. The results indicated that certain proteins in the GA may actually increase cancer cells' ability to migrate. The team wants to find methods to selectively disrupt this Golgi-related process in cancer cells. Such methods would prevent GA from promoting membrane vesicle movement and therefore halt cancer metastasis. According to the researchers, targeting certain cellular processes in the Golgi is a potential way to suppress tumor cell migration and metastasis. GA may be a novel target for cancer treatment. Flarebio offers: PAQR11 FITC conjugated antibody, Rabbit anti-human zinc finger E-box binding homeobox 1 polyclonal Antibody, Recombinant Mouse Zinc finger E-box-binding homeobox 1(Zeb1), Recombinant Mesocricetus auratus Zinc finger E-box-binding homeobox 1(ZEB1), Recombinant Mesocricetus auratus Zinc finger E-box-binding homeobox 1(ZEB1), Recombinant Human Zinc finger E-box-binding homeobox 1(ZEB1), or other molecules
